We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fresh Guidelines Issued for Red Blood Cell Transfusion

By LabMedica International staff writers
Posted on 09 Apr 2012
Wide variability in the use of transfusions in the United States indicates that in many settings patients are receiving unnecessary transfusions. More...


Evidence shows no difference in mortality, ability to walk independently, or length of hospital stay between patients on a liberal transfusion strategy or a restrictive strategy of red blood cell transfusions.

The AABB (formerly known as the American Association of Blood Banks; Bethesda, MD, USA), has recently updated its guidelines for a red blood cell transfusion strategy for stable adults and children. A 20-member panel of experts based their assessment on a systematic review of research published from 1950 to 2011 to determine optimal use of red blood cells to maximize clinical outcomes and avoid the harms and costs of unnecessary transfusions.

The panel examined the proportion of patients who received any red cell transfusion and the number of red cell units transfused to describe the impact of restrictive transfusion strategies on red blood cell usage. To determine the clinical consequences of a restrictive strategy, the scientists examined overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay.

They recommended that physicians should consider transfusing at a hemoglobin threshold of 7 to 8 g/dL. Physicians should also consider transfusion for patients with symptoms of anemia or a hemoglobin of less than or equal to 8 g/dL. However, the researchers caution that there was some uncertainty about risk for perioperative myocardial infarction associated with this approach. The panel found insufficient evidence to recommend a liberal or restrictive transfusion strategy for patients with acute coronary syndrome. While physicians most commonly use hemoglobin concentration to decide when to transfuse, the panel suggests that physicians also consider symptoms of anemia in their decision-making.

Jeffrey L. Carson, MD, from the Robert Wood Johnson Medical School, (New Brunswick, NJ, USA), and lead author of the guidelines, said, "Our recommendation is based on the evidence that restrictive transfusion is safe and associated with less blood use. Of course, clinical judgment is critical.

Physicians may choose to transfuse above or below the specified hemoglobin threshold based on individual patient characteristics.” Darrell J. Triulzi, MD, the president of AABB, added, "AABB believes that hospitals and clinicians can reduce the number of unnecessary transfusions. Implementing evidence-based transfusion is perhaps the most important step hospitals can take to achieve this goal." The guidelines were published in the March 26, 2012, online edition of the Annals of Internal Medicine.

Related Links:

AABB



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.